Journal of Clinical Oncology

Vol. 43, Issue 14 Issue 14 2025
17
Articles

Articles in this Issue

Risks of Organ Preservation in Rectal Cancer: Beyond Distant Metastases, Ultimate Local Failure Can Also Be a Problem

Joanna Socha, Krzysztof Bujko May 10, 2025 pp. 1742-1743 10.1200/jco-24-02518

Reply to: “Risks of Organ Preservation in Rectal Cancer: Beyond Distant Metastases, Ultimate Local Failure Can Also Be a Problem,” “Organ Preservation in Rectal Cancer: Fear of Risks Versus the Risks of Fear,” and “Distant Metastases With Nonoperative Management in Rectal Cancer: Challenges in Defining Risk”

Laura M. Fernandez, Guilherme P. São Julião, Carlos Cerdan-Santacruz et al. May 10, 2025 pp. 1746-1748 10.1200/jco-25-00132

Distant Metastases With Nonoperative Management in Rectal Cancer: Challenges in Defining Risk

Krishan R. Jethwa, Christopher L. Hallemeier, Nina N. Sanford May 10, 2025 pp. 1743-1745 10.1200/jco-24-02714

Organ Preservation in Rectal Cancer: Fear of Risks Versus the Risks of Fear

Julio Garcia-Aguilar, Hannah Williams, Martin R. Weiser et al. May 10, 2025 pp. 1745-1746 10.1200/jco-24-02723

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji et al. May 10, 2025 pp. 1631-1637 10.1200/jco-24-01673

In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-a...

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases

Sarah A. Weiss, Dijana Djureinovic, Wei Wei et al. May 10, 2025 pp. 1685-1694 10.1200/jco-24-02219

PURPOSE Anti–vascular endothelial growth factor therapy enhances PD-1 inhibitor activity in preclinical models and has been used to treat perilesional cerebral edema and radiation necrosis...

Erratum: Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis

Yutaka Yamamoto, Hiroji Iwata, Shigehira Saji et al. May 10, 2025 pp. 1749-1749 10.1200/jco-25-00722

They Not Like Us: Evaluating the Diverse Strategies in Locally Advanced Rectal Cancer Treatment

Pratik Shah, Tony Philip May 10, 2025 pp. 1620-1624 10.1200/jco-24-02178

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagn...

Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why?

Susan F. Slovin May 10, 2025 pp. 1617-1619 10.1200/jco-24-02402

Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study

Esther R. Berko, Arlene Naranjo, Alexander A. Daniels et al. May 10, 2025 pp. 1673-1684 10.1200/jco-24-02407

PURPOSE Relapsed high-risk neuroblastomas (NBLs) are enriched for targetable mutations in ALK and RAS-MAPK pathwa...

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

Daniel P. Petrylak, Raffaele Ratta, Nobuaki Matsubara et al. May 10, 2025 pp. 1638-1649 10.1200/jco-24-01283

PURPOSE The standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) t...

Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update

Ko Un Park, Mark R. Somerfield, Nirupama Anne et al. May 10, 2025 pp. 1720-1741 10.1200/jco-25-00099

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the...

Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Frederick L. Locke, Javier L. Munoz, Michael T. Tees et al. May 10, 2025 pp. 1695-1705 10.1200/jco-24-01933

PURPOSE Off-the-shelf, allogeneic CD19 chimeric antigen receptor (CAR) T-cell products may improve access to treatment versus autologous ones. We report the phase I experience of t...

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts

Sumanta K. Pal, Yohann Loriot, Andrea Necchi et al. May 10, 2025 pp. 1650-1662 10.1200/jco-24-01675

PURPOSE The COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab in advanced solid tumors. Presented here are results from the expansion cohorts with advance...

Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?

Yizhen Fu, Yaojun Zhang, Dandan Hu et al. May 10, 2025 pp. 1625-1630 10.1200/jco-24-02615

Risks of Organ Preservation in Rectal Cancer: Data From Two International Registries on Rectal Cancer

Laura M. Fernandez, Guilherme P. São Julião, Carlos Cerdan Santacruz et al. May 10, 2025 pp. 1663-1672 10.1200/jco.24.00405

PURPOSE Organ preservation has become an attractive alternative to surgery (total mesorectal excision [TME]) among patients with rectal cancer after neoadjuvant therapy who achieve a clini...

Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status

Matteo Lambertini, Eva Blondeaux, Loredana M. Tomasello et al. May 10, 2025 pp. 1706-1719 10.1200/jco-24-01334

PURPOSE To investigate the clinical behavior of breast cancer in young BRCA carriers according to the specific BRCA g...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page